Sponsors & Exhibitors of ISPNO 2022
We kindly thank all our supporters!
Pediatric Brain Tumor Foundation
The Pediatric Brain Tumor Foundation (www.curethekids.org) is one of the largest patient advocacy funders of pediatric brain tumor research in the U.S. Since 1991, PBTF’s funding has resulted in an improved understanding of childhood brain tumors, new therapies, and multi-million-dollar grants that multiply our impact and lead to more clinical trials. We invest in novel concepts brought forward by researchers around the world across basic, translational and survivorship science, clinical trials, core resources, and research meetings and collaboratives. A leading champion for patient families and survivors, PBTF offers resources for the entire family from the moment symptoms start, through treatment and beyond.
The Brain Tumour Charity
The Brain Tumour Charity is the world’s leading brain tumour charity and one of the largest dedicated funders of research into brain tumours globally. Our research strategy, Accelerating a Cure, is driven by our two goals: to double survival and halve the harm caused by brain tumours.
Our funding covers all areas of research into primary brain tumours, including basic science; translational and clinical research, including trials; quality of life; adult and paediatric; high- and low-grade tumour types.
By funding world-class researchers and connecting global experts, resources and ideas, we’re helping to advance our fundamental understanding of brain tumours and translate scientific discoveries for patient benefit.
Robert Connor Dawes (RCD) Foundation
The Robert Connor Dawes (RCD) Foundation was formed in June 2013 in the memory of Robert ‘Connor Dawes’ who at just 18 years of age, lost his 16-month battle with an ependymoma brain tumour.
Operating in Australia and the US, RCD has invested AU$5.09M into paediatric brain cancer research, funding basic science, translational projects, and fellowships, scholarships and travel grants.
It has leveraged another AU$10.5M leading collaborative research initiatives and partners with those who are equally as passionate about defeating this cruel disease.
The Morgan Adams Foundation
The Morgan Adams Foundation funds kids’ cancer research. We raise awareness of, and educate our communities about, the need for pediatric and young adult specific cancer treatments. Working with leading researchers and physicians, we fund new and innovative ideas that will improve cancer treatment effectiveness, overall outcomes, survival rates, and quality of life while minimizing the devastating side effects current treatments have on children. We have one purpose: to fund the best possible treatments for kids, adolescents, and young adults who have cancer.
medac is a privately held global pharmaceutical company with a continuously growing therapeutics and diagnostics business.
The Germany-based company provides a wide range of high-quality standard products as well as special therapeutics and innovative diagnostics. Being specialized in the treatment of haemato- and oncological, urological and autoimmune diseases, medac is committed to the refinement of existing and the development of new therapeutic products – providing patients with essential and individualized treatments.
medac as a brain cancer specialist has a broad product portfolio and is a competent and reliable partner not only for neurosurgery but also for neuro-oncology.
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. alexion.com
The Illumina mission is to improve human health by unlocking the power of the genome. Now, through innovation and collaboration, we are enabling genomic breakthroughs in immunotherapy, biomarker discovery, and therapy selection. The opportunity to transform tumor profiling with innovative assays that enable comprehensive genomic profiling, new companion diagnostic development, and liquid biopsy inspires us to push boundaries and drive innovation.
We lead global healthcare technology, boldly attacking the most challenging problems. Our Mission — to alleviate pain, restore health, and extend life —unites a global team of 90,000+ people, and our technologies transform the lives of two people every second, every hour, every day. Expect more from us.
Further Sponsors & Exhibitors
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com
Cancers (ISSN 2072-6694) is a peer-reviewed, open access journal of oncology, published semimonthly online by MDPI. It is indexed by the Science Citation Index Expanded (impact factor of 6.639 for 2021 and is ranked Q1: Oncology), Scopus, PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases. It publishes high-quality articles including basic, translational, and clinical studies on all tumor types. The Irish Association for Cancer Research (IACR), Signal Transduction Society (STS) and Spanish Association for Cancer Research (ASEICA) are affiliated with Cancers. The article types include Research Papers, Reviews, Editorials, Communications, etc.
Children’s Brain Tumor Network
The Children’s Brain Tumor Network (CBTN) is dedicated to driving innovative discovery, pioneering new treatments and accelerating open science to improve health for all children and young adults diagnosed with a brain tumor. By accelerating the pace of translational research and the discovery of new treatments, the CBTN is a global community with the shared goal to save children and young adults from brain tumors.
Day One Biopharmaceuticals Inc.
Day One is a biopharmaceutical company founded to address a critical unmet need- the dire lack of therapeutic development in pediatric cancers. Day One is committed to developing targeted therapies for patients with life-threatening diseases and redefine what’s possible for all people living with cancer, regardless of age, starting from Day One. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, selective type II pan-RAF inhibitor. The pipeline also includes pimasertib, an investigational, oral, selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2).
At Novartis, our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and digital technologies to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Renishaw Neuro Solutions
Renishaw Neuro Solutions enables direct-to-target delivery for a broad range of applications. Using the neuroinfuse™ drug delivery system, predictable and translatable intraparenchymal infusions in preclinical and clinical trials can become a reality.
Our Lab2Clinic™ service supports pharma and biotech through the preclinical journey, translation into clinical trials and scaled-up commercialisation. We have a wide geographical reach, and we focus on promoting long-term partnerships.
All this is underpinned by our FDA-cleared, CE-marked stereotactic products borne out of a +45-year precision engineering heritage.